Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome

Korean Journal of Internal Medicine

Volumn 24, Issue 4, 2009, Pages 330-336

  Yun, Kyeong Ho ^a   Shin, Ik Sang ^a   Rhee, Sang Jae ^a   Lee, Eun Mi ^a   Yoo, Nam Jin ^a   Kim, Nam Ho ^a   Oh, Seok Kyu ^a   Jeong, Jin Won ^a  

^a Wonkwang University Hospital   (South Korea)

Author keywords

Acute coronary syndrome; Hydroxymethylglutaryl CoA reductase inhibitor; Lipids; Triglycerides

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PROGNOSIS; REVASCULARIZATION; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHOLESTEROL, LDL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 72049093989     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.4.330     Document Type: Article

References (20)

1. Sacandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Cornary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
4. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients of coronary heart disease and a board range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
5. O'Keefe JH Jr, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol 2004;43:2142-2146. (Pubitemid 38686815)
6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504. (Pubitemid 38477774)
7. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732.
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
9. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008;101:1003-1008.
10. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28. (Pubitemid 40075677)
11. Park JS, Lee HJ, Kim YJ, et al. The epidemiological and clinical characteristics of patients admitted for coronary angiography to evaluate ischemic heart disease. Korean J Intern Med 2007;22:87-92.
12. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-318. (Pubitemid 30469857)
13. Masaki N, Tatami R, Kumamoto T, et al. Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. Int Heart J 2005;46:833-843.
14. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952. (Pubitemid 39208455)
15. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
16. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-458.
17. He Y, Lam TH, Li LS, Li LS, He SF, Liang BQ. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol 2004;14:1-7. (Pubitemid 37521242)
18. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-730. (Pubitemid 351221217)
19. Yu KC, Cooper AD. Postprandial lipoproteins and atherosclerosis. Front Biosci 2001;6:D332-D354.
20. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005;12:1931-1945.